Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

112 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
WT1 as a novel target antigen for cancer immunotherapy.
Oka Y, Tsuboi A, Elisseeva OA, Udaka K, Sugiyama H. Oka Y, et al. Among authors: udaka k. Curr Cancer Drug Targets. 2002 Mar;2(1):45-54. doi: 10.2174/1568009023334088. Curr Cancer Drug Targets. 2002. PMID: 12188920 Review.
Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies.
Elisseeva OA, Oka Y, Tsuboi A, Ogata K, Wu F, Kim EH, Soma T, Tamaki H, Kawakami M, Oji Y, Hosen N, Kubota T, Nakagawa M, Yamagami T, Hiraoka A, Tsukaguchi M, Udaka K, Ogawa H, Kishimoto T, Nomura T, Sugiyama H. Elisseeva OA, et al. Among authors: udaka k. Blood. 2002 May 1;99(9):3272-9. doi: 10.1182/blood.v99.9.3272. Blood. 2002. PMID: 11964293 Free article.
Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues.
Tsuboi A, Oka Y, Udaka K, Murakami M, Masuda T, Nakano A, Nakajima H, Yasukawa M, Hiraki A, Oji Y, Kawakami M, Hosen N, Fujioka T, Wu F, Taniguchi Y, Nishida S, Asada M, Ogawa H, Kawase I, Sugiyama H. Tsuboi A, et al. Among authors: udaka k. Cancer Immunol Immunother. 2002 Dec;51(11-12):614-20. doi: 10.1007/s00262-002-0328-9. Epub 2002 Oct 18. Cancer Immunol Immunother. 2002. PMID: 12439606 Free PMC article.
Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis.
Oka Y, Tsuboi A, Murakami M, Hirai M, Tominaga N, Nakajima H, Elisseeva OA, Masuda T, Nakano A, Kawakami M, Oji Y, Ikegame K, Hosen N, Udaka K, Yasukawa M, Ogawa H, Kawase I, Sugiyama H. Oka Y, et al. Among authors: udaka k. Int J Hematol. 2003 Jul;78(1):56-61. doi: 10.1007/BF02983241. Int J Hematol. 2003. PMID: 12894852 Clinical Trial.
WT1 peptide-based immunotherapy for patients with lung cancer: report of two cases.
Tsuboi A, Oka Y, Osaki T, Kumagai T, Tachibana I, Hayashi S, Murakami M, Nakajima H, Elisseeva OA, Fei W, Masuda T, Yasukawa M, Oji Y, Kawakami M, Hosen N, Ikegame K, Yoshihara S, Udaka K, Nakatsuka S, Aozasa K, Kawase I, Sugiyama H. Tsuboi A, et al. Among authors: udaka k. Microbiol Immunol. 2004;48(3):175-84. doi: 10.1111/j.1348-0421.2004.tb03503.x. Microbiol Immunol. 2004. PMID: 15031530 Free article.
Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression.
Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H, Elisseeva OA, Oji Y, Kawakami M, Ikegame K, Hosen N, Yoshihara S, Wu F, Fujiki F, Murakami M, Masuda T, Nishida S, Shirakata T, Nakatsuka S, Sasaki A, Udaka K, Dohy H, Aozasa K, Noguchi S, Kawase I, Sugiyama H. Oka Y, et al. Among authors: udaka k. Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13885-90. doi: 10.1073/pnas.0405884101. Epub 2004 Sep 13. Proc Natl Acad Sci U S A. 2004. PMID: 15365188 Free PMC article. Clinical Trial.
Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes.
Fujiki F, Oka Y, Tsuboi A, Kawakami M, Kawakatsu M, Nakajima H, Elisseeva OA, Harada Y, Ito K, Li Z, Tatsumi N, Sakaguchi N, Fujioka T, Masuda T, Yasukawa M, Udaka K, Kawase I, Oji Y, Sugiyama H. Fujiki F, et al. Among authors: udaka k. J Immunother. 2007 Apr;30(3):282-93. doi: 10.1097/01.cji.0000211337.91513.94. J Immunother. 2007. PMID: 17414319
WT1 (Wilms' tumor 1) peptide immunotherapy for renal cell carcinoma.
Iiyama T, Udaka K, Takeda S, Takeuchi T, Adachi YC, Ohtsuki Y, Tsuboi A, Nakatsuka S, Elisseeva OA, Oji Y, Kawakami M, Nakajima H, Nishida S, Shirakata T, Oka Y, Shuin T, Sugiyama H. Iiyama T, et al. Among authors: udaka k. Microbiol Immunol. 2007;51(5):519-30. doi: 10.1111/j.1348-0421.2007.tb03940.x. Microbiol Immunol. 2007. PMID: 17579261 Free article. Clinical Trial.
Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma.
Tsuboi A, Oka Y, Nakajima H, Fukuda Y, Elisseeva OA, Yoshihara S, Hosen N, Ogata A, Kito K, Fujiki F, Nishida S, Shirakata T, Ohno S, Yasukawa M, Oji Y, Kawakami M, Morita S, Sakamoto J, Udaka K, Kawase I, Sugiyama H. Tsuboi A, et al. Among authors: udaka k. Int J Hematol. 2007 Dec;86(5):414-7. doi: 10.1007/BF02983998. Int J Hematol. 2007. PMID: 18192109
Cancer immunotherapy targeting Wilms' tumor gene WT1 product.
Oka Y, Udaka K, Tsuboi A, Elisseeva OA, Ogawa H, Aozasa K, Kishimoto T, Sugiyama H. Oka Y, et al. Among authors: udaka k. J Immunol. 2000 Feb 15;164(4):1873-80. doi: 10.4049/jimmunol.164.4.1873. J Immunol. 2000. PMID: 10657636
112 results